While the most important decisions made by the FDA in December were undoubtedly the Emergency Use Authorizations for two COVID-19 vaccines, the month also saw a number of firsts on the regulatory front, including the authorization of the first test allowing for at-home collection of patient samples to detect both COVID-19 and influenza A and B. Now, today’s article takes a look at the biotech companies awaiting FDA decisions in January. For more, CLICK HERE.
